Loading…
EOLS
Evolus, Inc.
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic
$8.880.00%
Key metrics
- Market cap
- $586.53M
- P/E
- —
- Forward P/E
- 32.2x
- P/B
- —
- Dividend yield
- —
- EPS
- -$0.53
- ROE
- —
- Profit margin
- -10.85%
- Revenue growth
- +21.20%
- Beta
- 1.36
- 52-week high
- $9.12
- 52-week low
- $3.86
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
- 353
- Newport Beach, United States
Company description provided by Yahoo Finance.